ArticleFrontiers in immunology2026
Accumulation of small peritoneal macrophages and dendritic cells in a concomitant immunity model associated with prolonged survival.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated the contribution of peritoneal macrophages to tumor control using a DBA/2-SL2 murine model of concomitant tumor immunity. Methods: Female DBA/2 mice were subjected to a concomitant tumor model in which SL2 lymphoma cells were injected subcutaneously (SC) to establish a primary tumor, followed by intraperitoneal (IP) SL2 challenge to induce secondary tumors. Peritoneal immune cells were analyzed by flow cytometry 4 days after IP challenge. Absolute cell numbers were calculated from total viable cell recovery. To assess functional antitumor activity, CD11b Results: Prolonged survival in mice with secondary IP SL2 tumors was associated with pronounced alterations in peritoneal immune composition. Flow cytometric analysis revealed a marked accumulation of small peritoneal macrophages (SPMs) and dendritic cells (DCs) in mice with secondary IP tumors. Absolute counts of SPMs (CD11b Conclusion: Prolonged survival of DBA/2 mice with secondary IP SL2 tumors is associated with a distinct peritoneal immune landscape characterized by accumulation of SPMs and DCs. While macrophages alone were insufficient to control tumor growth, repeated IP tumor challenge suggested a trend toward systemic antitumor activity. Collectively, these findings highlight SPMs and DCs as prominent cells associated with survival benefit in this model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.